Current Developments and Future Opportunities
What is Acute Myeloid Leukemia?
Acute Myeloid Leukemia (AML) is a uniquely challenging disease in which 50-80% patients eventually relapse following induction and/or post-remission therapies and with 5-year survival rate of merely 30%. Drug development in AML has been challenging in the past, with multiple failures and modest commercial success. Despite that, there exists significant unmet need, presenting vast scope for drug development and potential for large commercial opportunity.
Multiple MoAs and drug modalities are being investigated for AML, however assets with safe/tolerable profile and non-overlapping toxicity with SoC therapies could have an edge as combination strategies in different patient segments.
Publication
Download the publication
Are you interested in learning more about this indication including current strategies being adopted by drug developers or four broad segments that present key opportunities to alter the AML treatment paradigm?
